KRAS and neuroendocrine carcinoma: TP53 (32.9%), KRAS (5.5%), and BRAF (4.1%) mutations were detected in all tumour groups, with NEC ≥55% being more common (76.7%) than in the other two groups (55.6% for NEC <55% and 20% for NET).